Home » Stocks » ISR

IsoRay, Inc. (ISR)

Stock Price: $0.860 USD -0.090 (-9.47%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Pre-market: $0.850 -0.010 (-1.16%) Apr 19, 5:26 AM
Market Cap 121.43M
Revenue (ttm) 9.90M
Net Income (ttm) -3.32M
Shares Out 83.05M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $0.860
Previous Close $0.950
Change ($) -0.090
Change (%) -9.47%
Day's Open 0.932
Day's Range 0.810 - 0.965
Day's Volume 4,059,413
52-Week Range 0.352 - 2.810

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed V...

5 days ago - GlobeNewsWire

RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray's Cesi...

2 weeks ago - GlobeNewsWire

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -0.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT

2 months ago - GlobeNewsWire

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

Other stocks mentioned: ABML, GHSI, NMGRF, OBSV, SB, ZOM
2 months ago - InvestorPlace

RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the b...

3 months ago - GlobeNewsWire

Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido...

Other stocks mentioned: CHNG, AIKI
3 months ago - Benzinga

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Canc...

4 months ago - GlobeNewsWire

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Revenue Increased 3% Year-Over-Year

5 months ago - GlobeNewsWire

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT

5 months ago - GlobeNewsWire

RICHLAND, Wash., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding trea...

5 months ago - GlobeNewsWire

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year

7 months ago - GlobeNewsWire

RICHLAND, Wash., Sept. 16, 2020 (GLOBE NEWSWIRE) --   Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options througho...

7 months ago - GlobeNewsWire

Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT

7 months ago - GlobeNewsWire

Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection

10 months ago - GlobeNewsWire

IsoRay (ISR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-ri...

10 months ago - GlobeNewsWire

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 4.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year

11 months ago - GlobeNewsWire

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes...

11 months ago - GlobeNewsWire

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

IsoRay Is Set For Further Growth

1 year ago - Seeking Alpha

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -7.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

IsoRay: Turned Around And Growing

1 year ago - Seeking Alpha

Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients...

1 year ago - GlobeNewsWire

IsoRay Likely Has Further To Rise

1 year ago - Seeking Alpha

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of 50.00% and 4.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is sche...

1 year ago - GlobeNewsWire

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 5.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy

1 year ago - GlobeNewsWire

Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2%Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date

1 year ago - GlobeNewsWire

RICHLAND, WASHINGTON, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throug...

1 year ago - GlobeNewsWire

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About ISR

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which pri... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1983
CEO
Dwight Babcock
Employees
53
Stock Exchange
NYSEAMERICAN
Ticker Symbol
ISR
Full Company Profile

Financial Performance

In 2020, IsoRay's revenue was $9.68 million, an increase of 32.35% compared to the previous year's $7.31 million. Losses were -$3.45 million, -33.01% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IsoRay stock is "Strong Buy." The 12-month stock price forecast is 2.17, which is an increase of 152.33% from the latest price.

Price Target
$2.17
(152.33% upside)
Analyst Consensus: Strong Buy